What Are the Risks of COVID Vaccines and Heart Events?

mRNA COVID-19 vaccines carry a small but genuine risk of heart inflammation, primarily myocarditis and pericarditis, that is concentrated in younger males after their second dose. The absolute numbers are low, on the order of a few cases per hundred thousand doses in the general population, but the risk is not zero and is high enough in certain demographic groups that it has reshaped vaccination strategies in several countries. At the same time, the heart risks from a COVID-19 infection itself are substantially larger than those from vaccination, a comparison that is central to understanding the full picture.

How Common Is Vaccine-Related Heart Inflammation

Across the general vaccinated population, the rate of myocarditis or pericarditis after an mRNA vaccine is roughly 5 per 100,000 people who received at least one dose, based on a Spanish retrospective study that also found a much higher incidence of 200 per 100,000 among people who actually caught COVID-19.¹ A large U.S. cohort study that tracked over 15 million people aged 18 to 64 found 411 combined myocarditis or pericarditis events across roughly 27.5 million doses of the two main mRNA vaccines.² These numbers are small enough that most vaccinated people will never encounter the problem, but they are consistent enough across countries and datasets that the signal is considered real, not statistical noise.

The risk is not evenly distributed across doses. Within the first week after any given shot, the odds of myocarditis go up compared to baseline. For the Pfizer vaccine’s first dose, the increase is modest. For the Moderna vaccine’s second dose, the odds ratio in one French study reached about 22 compared to an unvaccinated baseline, meaning the risk was substantially elevated in that short window.³ That sounds alarming in isolation, but the baseline rate of myocarditis in any given week is extremely low, so even a twentyfold increase translates to a small number of actual cases.

Who Faces the Highest Risk

Young males are disproportionately affected, and the pattern is one of the most consistent findings in the entire vaccine-safety literature. Among males aged 12 to 17, one systematic review found the highest estimates of vaccine-associated myocarditis reached about 37 to 39 cases per 100,000 people after the second Pfizer dose.⁴ Canadian surveillance data found roughly 66 reports per million doses in males aged 12 to 17 after the second shot, far higher than the expected background rate of about 2.4 cases per million.⁵ In men aged 18 to 25, the U.S. cohort study found the highest incidence rates after the second dose for both Pfizer and Moderna vaccines.²

One leading explanation for this sex difference involves testosterone, which appears to modulate the immune response in ways that make the heart muscle more vulnerable to inflammatory damage in young men.⁶ This is consistent with the broader observation in cardiology that myocarditis from any cause, not just vaccines, hits young men harder than other groups.

How Vaccine Myocarditis Compares to COVID Myocarditis

A systematic review and meta-analysis directly comparing the two found that the relative risk of myocarditis was more than seven times higher after COVID-19 infection than after vaccination.⁷ The Spanish hospital study paints a similar picture: myocarditis and pericarditis occurred at a rate of about 200 per 100,000 in COVID-19 patients, compared to 5 per 100,000 in vaccinated individuals.¹ Even among adolescents, where vaccine myocarditis rates are highest relative to other age groups, the rate in unvaccinated teens was about double that of vaccinated teens in the same study.

This comparison matters because it frames the practical question most people actually face: not “is there a risk?” but “is the risk larger or smaller than the alternative?” For most people, the heart risks of catching COVID without vaccination are meaningfully worse than the heart risks of the vaccine itself.

What Happens When Vaccine Myocarditis Occurs

The typical presentation is chest pain a few days after vaccination, often with elevated troponin levels (a blood marker of heart-muscle injury). In a large Israeli healthcare organization study, about three quarters of confirmed myocarditis cases were classified as mild, and roughly a fifth as intermediate. One case involved cardiogenic shock, a serious condition where the heart cannot pump enough blood. After a median follow-up of 83 days, one patient had been readmitted and one had died of an unknown cause after discharge.⁸

Most people who develop vaccine-related myocarditis are hospitalized, but their stays tend to be short. Australian surveillance data found a median hospital stay of two days, with about 4% needing intensive care. No deaths were recorded in that cohort. However, the picture was not entirely clean at follow-up: about 60% of patients reported ongoing symptoms like chest pain, palpitations, or shortness of breath at three to six months, though that figure dropped to about 35% by 12 to 18 months. The proportion needing medication fell sharply from over 90% at discharge to about 13% at a year and a half.⁹

A U.S. surveillance study of adolescents and young adults followed nearly 520 confirmed cases. About 93% were hospitalized, and a quarter of those required intensive care. No deaths occurred during follow-up, and only a small fraction were readmitted for cardiac reasons.¹⁰ The overall pattern is encouraging but imperfect: most people recover well, but a meaningful minority has lingering symptoms for months.

The Question of Lasting Heart Damage

Even when someone feels better, imaging can sometimes tell a more complicated story. A study using cardiac MRI found that about 30% of patients who had experienced vaccine-associated myocarditis showed evidence of myocardial scarring (late gadolinium enhancement) on follow-up scans, most commonly in the lower-side wall of the heart. The pattern of scarring was typically in the outer or middle layers of the heart wall rather than the inner layer. Despite this, all patients had normal inflammatory markers on their follow-up scans, and most had normal or near-normal heart function.¹¹

What that scarring means over the long term is an open question. In other forms of myocarditis, cardiac scarring can predispose people to arrhythmias or heart failure years later. Whether the same applies to these relatively small areas of vaccine-associated scarring is something researchers are still watching. The finding is a reason for continued follow-up rather than immediate alarm, but it does mean that describing vaccine myocarditis as universally “mild and self-limiting” oversimplifies things.

Sudden Cardiac Death Fears

One of the most emotionally charged concerns has been whether mRNA vaccines cause sudden cardiac death in young people. A state-level investigation in Oregon examined all 1,292 deaths among people aged 16 to 30 during an 18-month period when vaccines were widely available. Not a single death certificate listed vaccination as either a direct or contributing cause of death.¹² That is a meaningful null result given the size of the sample and the intensity of scrutiny.

A Finnish nationwide study took a different approach, reviewing all 428 medicolegal autopsy cases that mentioned a COVID-19 vaccination history. After detailed investigation by forensic pathologists, vaccination was considered a potential contributing factor in only 12 cases, and only five of those listed it as the underlying cause of death.¹³ Finland administered millions of vaccine doses during the study period, so the absolute risk of a fatal outcome, while not zero, is extraordinarily small.

How the Mechanism Works

Researchers have proposed several ways the vaccines might trigger heart inflammation, though the science here is still evolving. The leading theory involves molecular mimicry: the spike protein that mRNA vaccines teach your cells to produce shares structural similarities with certain proteins found in heart tissue. A 2025 study published in Circulation demonstrated that T cells from patients with vaccine-associated myocarditis recognized spike protein fragments that closely resembled sequences from a potassium channel expressed in heart cells. When researchers introduced one of these mimicking fragments into mice, it induced myocarditis.¹⁴

Another piece of the puzzle involves free-floating spike protein. In adolescents who developed myocarditis after vaccination, researchers detected elevated levels of unbound spike protein in the blood, whereas no free spike was found in vaccinated individuals who did not develop symptoms.¹⁵ The implication is that in most people, antibodies quickly bind and neutralize the spike protein, but in rare cases the immune system may not clear it fast enough, allowing it to circulate and potentially interact with heart tissue.

Other proposed mechanisms include the spike protein transiently disrupting a receptor called ACE2 that is involved in blood pressure regulation and vascular function¹⁶, and broader dysregulated immune activation.¹⁷ These mechanisms are not mutually exclusive and may act together in susceptible individuals.

Spacing Out Doses Reduces the Risk

One of the most actionable findings to emerge from safety research is that longer intervals between vaccine doses lower the chance of myocarditis. A French study found that when the gap between the first and second Pfizer dose was extended beyond seven weeks, the risk of myocarditis dropped by roughly a factor of four compared to intervals shorter than three weeks. A similar reduction was seen for the booster dose.³ This finding has been influential: several countries now recommend extended intervals between mRNA vaccine doses, particularly for younger age groups, as a way to reduce myocarditis risk while still providing strong immunity.¹⁸

The study also found that while the risk goes up after first, second, and booster doses, the booster-dose risk was lower than the second-dose risk for both vaccines. Odds ratios after the third dose of Pfizer were about 4.2, compared to higher values after the second dose.¹⁹ An English self-controlled case series found that elevated risk after a booster depended partly on which vaccine was used for priming, with higher signals when both the primary course and the booster were mRNA-based.²⁰

Adenoviral Vector Vaccines and a Different Heart Risk

The Johnson & Johnson and AstraZeneca vaccines used a different technology, adenoviral vectors, and came with a different cardiac-adjacent risk: vaccine-induced immune thrombotic thrombocytopenia, or VITT. This rare syndrome involved blood clots forming in unusual locations, particularly the brain’s venous sinuses and the abdominal veins, accompanied by a dangerous drop in platelet counts.²¹ The condition was first reported in early 2021 and led to temporary pauses and eventual restrictions on these vaccines in multiple countries.

VITT was triggered by antibodies targeting a protein called platelet factor 4 (PF4), though research showed that most of these antibodies were transient rather than persistent.²² In the U.S., the FDA paused Johnson & Johnson’s vaccine in April 2021 after reports of thrombosis and low platelets, including cases of pulmonary embolism and stroke shortly after vaccination.²³ Since these vector-based vaccines have largely been phased out in favor of updated mRNA formulations, VITT is mostly a historical concern at this point, but it illustrates that different vaccine platforms carry different cardiac and vascular risk profiles.

What About the Novavax Protein-Based Vaccine

Some people have assumed that protein-based vaccines like Novavax, which deliver a pre-formed spike protein rather than instructing cells to make one, would sidestep the myocarditis issue entirely. The data suggest otherwise. An analysis of global safety reports found that Novavax actually showed a higher disproportionality signal for myopericarditis than even the mRNA vaccines in some comparisons, though the total number of Novavax doses administered globally was much smaller, making these estimates less stable. Interestingly, the AstraZeneca adenoviral vector vaccine did not show an elevated signal for myopericarditis in the same analysis.²⁴ The takeaway is that the spike protein itself, regardless of the delivery platform, seems to be a relevant factor in triggering heart inflammation in susceptible individuals.

People With Pre-Existing Heart Conditions

You might expect that people with existing heart disease would be at the greatest risk from vaccine-related cardiac side effects, and there is genuine reason for caution. A review article examining whether COVID vaccine side effects can worsen pre-existing heart conditions concluded that the short-term risk of severe cardiovascular events is relatively low, but called for more research into long-term effects in people with underlying cardiac issues.²⁵

A large propensity-matched cohort study of older adults with coronary artery disease and heart failure painted a more reassuring picture. Vaccination was linked to lower all-cause mortality in a dose-dependent manner, fewer hospitalizations for heart failure, and lower rates of heart procedures like bypass surgery and stenting. There was no significant association with heart attacks, strokes, or blood clots. A small increase in myocarditis risk was observed, but overall the cardiovascular benefits substantially outweighed the risks in this population.²⁶ A study of U.S. veterans found that the absolute benefit of vaccination was generally greater for people with comorbid health conditions than for those without.²⁷

In other words, people with existing heart disease have more to gain from avoiding a COVID-19 infection, and the vaccine helps them do that. The small myocarditis signal does not disappear for them, but the math of risk versus benefit tilts even more strongly in favor of vaccination.

How Vaccine Myocarditis Is Treated

There are no randomized controlled trials of treatments specifically for vaccine-associated myocarditis. In practice, management follows standard myocarditis guidelines. Chest pain is typically treated with anti-inflammatory drugs like ibuprofen or colchicine.²⁸ In more severe cases, corticosteroids have been used, though the evidence for their effectiveness in this specific setting remains anecdotal.²⁹ Exercise restriction is nearly universal during recovery: the Australian data showed that about two thirds of patients were advised to limit physical activity at discharge, though that figure dropped to less than 10% by 18 months, and by then the restrictions were self-imposed rather than clinician-directed.⁹

Vaccine-Related Myocarditis in Historical Context

Heart inflammation after vaccination is not unique to COVID-19 vaccines. The smallpox vaccine, used extensively in military populations, was long recognized as a cause of myopericarditis. A case series from U.S. military personnel established a baseline rate of heart inflammation among first-time recipients of the vaccinia virus vaccine, with similar patterns of inflammatory cell infiltration in the heart tissue.³⁰ What distinguishes the COVID-19 vaccine situation is not the phenomenon itself but the scale of surveillance. Billions of doses administered worldwide, combined with modern electronic health records and active safety monitoring systems, made it possible to detect and quantify a risk that would have been invisible in earlier vaccination campaigns. The spike protein’s involvement in cardiac effects also shows up in the virus itself: lab work has shown that spike proteins can activate clotting pathways, trigger inflammation in blood vessel lining cells, and induce markers of vascular injury, which helps explain why both infection and vaccination can affect the cardiovascular system.³¹ The difference is one of dose and duration: infection exposes the body to far more spike protein over a longer period than a vaccine does, which goes a long way toward explaining why infection-related heart damage is consistently more common and often more severe.

1
PubMed. Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital
2
PubMed Central. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
3
PubMed Central. Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis
4
PubMed Central. COVID‐19 vaccine induced myocarditis in young males: A systematic review
5
PubMed Central. Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
6
PubMed Central. COVID-19 vaccine-associated myocarditis
7
PubMed Central. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis
8
PubMed Central. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
9
PubMed Central. Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia
10
PubMed Central. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
11
PubMed Central. Improved diagnosis of COVID-19 vaccine-associated myocarditis with cardiac scarring identified by cardiac magnetic resonance imaging
12
Morbidity and Mortality Weekly Report. Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine — Oregon, June 2021–December 2022
13
Vaccine: X. COVID-19 vaccination as a rare potential etiology for cause of death after medicolegal autopsy. A Finnish nationwide study.
14
PubMed Central. Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination
15
PubMed Central. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis
16
PubMed Central. Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection
17
PubMed Central. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
18
PubMed Central. Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents
19
Nature Communications. Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis
20
PubMed Central. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England
21
Open Access Journal of Microbiology & Biotechnology. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Where does The PF4 Fit?
22
PubMed Central. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
23
PubMed Central. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine
24
PubMed Central. Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
25
PubMed. Can adverse cardiac events of the COVID-19 vaccine exacerbate preexisting diseases?
26
PubMed Central. COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study
27
JAMA Internal Medicine. 2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans
28
Canadian Journal of Cardiology. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination: 2024 Status and Management Update
29
PubMed Central. Myocarditis following COVID ‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective
30
JAMA. Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel
31
PubMed Central. SARS-CoV-2 Spike Proteins and Cell-Cell Communication Induce P-Selectin and Markers of Endothelial Injury, NETosis, and Inflammation in Human Lung Microvascular Endothelial Cells and Neutrophils